Cargando…
Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients
BACKGROUND: In monarchE and Postoperative Therapy with Endocrine and TS‐1 (POTENT) trials, abemaciclib and S‐1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the criteria are at high risk of recurrence compared to no...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315737/ https://www.ncbi.nlm.nih.gov/pubmed/37162105 http://dx.doi.org/10.1002/cam4.6006 |
_version_ | 1785067561702916096 |
---|---|
author | Yu, Muhan Takada, Mamoru Yamada, Hideyuki Fujimoto, Hiroshi Sakakibara, Junta Yamamoto, Hiroto Nagashima, Takeshi Ohtsuka, Masayuki |
author_facet | Yu, Muhan Takada, Mamoru Yamada, Hideyuki Fujimoto, Hiroshi Sakakibara, Junta Yamamoto, Hiroto Nagashima, Takeshi Ohtsuka, Masayuki |
author_sort | Yu, Muhan |
collection | PubMed |
description | BACKGROUND: In monarchE and Postoperative Therapy with Endocrine and TS‐1 (POTENT) trials, abemaciclib and S‐1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the criteria are at high risk of recurrence compared to non‐eligible patients is still unknown. Here, we investigated recurrence risk according to the criteria of each trial in Japanese patients. METHODS: We reviewed the records of 992 patients who received surgery at Chiba University Hospital for stage I–III BC from January 2017 to May 2022 and selected 553 analytic cohort patients and retrospectively analyzed the relapse‐free survival of the patients as the primary endpoint. High‐recurrence risk was defined according to monarchE trial and POTENT trial. RESULTS: The 5‐year RFS for monarchE cohort 1 and cohort 2 eligible patients were 77.78% and 89.33%, respectively, which were significantly lower than monarchE non‐eligible patients (98.31%; p < 0.0001). However, the 5‐year RFS rate for POTENT eligible patients (90.51%) was lower than for POTENT non‐eligible patients (98.75%; p = 0.0001); excluding those who met the monarchE criteria, the prognosis of POTENT eligible patients had no significant differences from the prognosis of patients with POTENT non‐eligible BC (p = 0.3100). CONCLUSION: MonarchE criteria accurately identify patients who are prone to relapse. Moreover, although POTENT criteria also suggested a reasonable capacity for recurrence prediction, there was no significant difference in recurrence between POTENT non‐eligible patients and the patients who were POTENT but not monarchE eligible. This might offer justification for reconsidering the use of S‐1 in monarchE non‐eligible patients. |
format | Online Article Text |
id | pubmed-10315737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103157372023-07-04 Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients Yu, Muhan Takada, Mamoru Yamada, Hideyuki Fujimoto, Hiroshi Sakakibara, Junta Yamamoto, Hiroto Nagashima, Takeshi Ohtsuka, Masayuki Cancer Med RESEARCH ARTICLES BACKGROUND: In monarchE and Postoperative Therapy with Endocrine and TS‐1 (POTENT) trials, abemaciclib and S‐1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the criteria are at high risk of recurrence compared to non‐eligible patients is still unknown. Here, we investigated recurrence risk according to the criteria of each trial in Japanese patients. METHODS: We reviewed the records of 992 patients who received surgery at Chiba University Hospital for stage I–III BC from January 2017 to May 2022 and selected 553 analytic cohort patients and retrospectively analyzed the relapse‐free survival of the patients as the primary endpoint. High‐recurrence risk was defined according to monarchE trial and POTENT trial. RESULTS: The 5‐year RFS for monarchE cohort 1 and cohort 2 eligible patients were 77.78% and 89.33%, respectively, which were significantly lower than monarchE non‐eligible patients (98.31%; p < 0.0001). However, the 5‐year RFS rate for POTENT eligible patients (90.51%) was lower than for POTENT non‐eligible patients (98.75%; p = 0.0001); excluding those who met the monarchE criteria, the prognosis of POTENT eligible patients had no significant differences from the prognosis of patients with POTENT non‐eligible BC (p = 0.3100). CONCLUSION: MonarchE criteria accurately identify patients who are prone to relapse. Moreover, although POTENT criteria also suggested a reasonable capacity for recurrence prediction, there was no significant difference in recurrence between POTENT non‐eligible patients and the patients who were POTENT but not monarchE eligible. This might offer justification for reconsidering the use of S‐1 in monarchE non‐eligible patients. John Wiley and Sons Inc. 2023-05-10 /pmc/articles/PMC10315737/ /pubmed/37162105 http://dx.doi.org/10.1002/cam4.6006 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Yu, Muhan Takada, Mamoru Yamada, Hideyuki Fujimoto, Hiroshi Sakakibara, Junta Yamamoto, Hiroto Nagashima, Takeshi Ohtsuka, Masayuki Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients |
title | Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients |
title_full | Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients |
title_fullStr | Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients |
title_full_unstemmed | Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients |
title_short | Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients |
title_sort | less necessity of adjuvant s‐1 treatment in non‐monarche‐eligible patients |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315737/ https://www.ncbi.nlm.nih.gov/pubmed/37162105 http://dx.doi.org/10.1002/cam4.6006 |
work_keys_str_mv | AT yumuhan lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients AT takadamamoru lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients AT yamadahideyuki lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients AT fujimotohiroshi lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients AT sakakibarajunta lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients AT yamamotohiroto lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients AT nagashimatakeshi lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients AT ohtsukamasayuki lessnecessityofadjuvants1treatmentinnonmonarcheeligiblepatients |